H-IMMUNE THERAPEUTICS
H-Immune Therapeutics is an early stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Utilizing an immunotherapeutic approach, the company is exploring the development of novel, fully human antibody-based blockade therapeutics in an effort to generate new immuno-oncology treatments.
H-IMMUNE THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2016-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.h-immune.com
Status:
Active
Technology used in webpage:
LetsEncrypt Apache Amazon Route 53 Black Lotus
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Helsinn Birex Therapeutics
Helsinn Birex Therapeutics markets and sells pharmaceutical products.
Leuvas Therapeutics
Leuvas Therapeutics is a recently established biopharmaceutical company.
SimPharma
SimPharma is an early stage biopharma company based in Singapore.
More informations about "H-Immune Therapeutics"
HiFiBiO Therapeutics Acquires H-Immune Therapeutics
Oct 15, 2018 About H-Immune Therapeutics. Established in 2016, as a spin‐out of the French Atomic Energy Commission by Co‐founders Luc Boblet, PhD, (former Co‐founder and CEO of …See details»
H-Immune Therapeutics - Ownership and Business Overview - Mergr
Oct 15, 2018 H-Immune Therapeutics was founded in 2016. Life Science M&A Summary in 2018 Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2018 .See details»
H-Immune Therapeutics - PitchBook
H-Immune Therapeutics General Information Description. Developer of immuno-oncology therapeutics intended to create diverse antibody treatments. The company is engaged in the …See details»
HiFiBiO buys up H-Immune, joining forces to ‘combat cancer’
Oct 15, 2018 The company in its crosshairs is H-Immune which, back in 2016, was spun out of the French Atomic Energy Commission, and founded by Luc Boblet, Ph.D., the former co …See details»
H-Immune Therapeutics (FR) - life-sciences-europe.com
Jan 1, 2016 Advertisement. Organisation › Details H-Immune Therapeutics (FR) Established in 2016, as a spin-out of the French Atomic Energy Commission by Co-founders Luc Boblet, …See details»
HiFiBiO acquires H-Immune Therapeutics - 2018-10-15 - Crunchbase
Acquired Organization: H-Immune Therapeutics H-Immune Therapeutics is an early stage biopharmaceutical company. Acquiring Organization:See details»
H-Immune Therapeutics | Biopharma, Biotechnology, Health Care ...
H-Immune Therapeutics is an early stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Utilizing an immunotherapeutic …See details»
H-Immune SAS - Drug pipelines, Patents, Clinical trials - Synapse
Explore H-Immune SAS with its drug pipeline, therapeutic area, technology platform, 2 news.See details»
H-Immune Therapeutics - Crunchbase
H-Immune Therapeutics is an early stage biopharmaceutical company. Start Free Trial . Chrome ExtensionSee details»
H-Immune - VentureRadar
LucasPye Bio USA n/a As a Contract Development Manufacturing Organization (CDMO), we fast-track the clinical development of your biologic for regulatory approval, manufacture your …See details»
H-IMMUNE (PARIS 14) Chiffre d'affaires, résultat, bilans sur …
H-IMMUNE, société par actions simplifiée, au capital social de 1245056,00 EURO, dont le siège social est situé au 29 RUE DU FG SAINT JACQUES, 75014 PARIS, immatriculée au Registre …See details»
h-immune - Startup France French Tech Grand Paris - Les Pépites …
Jun 12, 2018 H-IMMUNE: ÉTABLIR UN RÔLE ÉMERGENT EN IMMUNO-ONCOLOGIE. H-Immune est une société biopharmaceutique en phase de démarrage engagée dans le …See details»
HiFiBiO bags immuno-oncology specialist H-Immune
Oct 16, 2018 HiFiBiO bags immuno-oncology specialist H-Immune Multinational biotherapeutics company HiFiBiO Therapeutics announced that it has taken over early stage biotech H …See details»
H-immune: améliorer le système immunitaire humain pour
Du coup, H-Immune vend l’accès à sa plateforme aux équipes qui peuvent en avoir besoin, ce qui a permis de dégager un million d’euros de chiffre d’affaires dès 2017. Les fonds serviront ...See details»
HiFiBiO Therapeutics Acquires H-Immune Therapeutics
Oct 15, 2018 About H-Immune Therapeutics Established in 2016, as a spin‐out of the French Atomic Energy Commission by Co‐founders Luc Boblet, PhD, (former Co‐founder and CEO of …See details»
Pierre Fabre and H-Immune to develop new cancer …
Mar 21, 2017 The agreement will give Pierre Fabre access to H-Immune’s IVI technology for three different discovery programmes in the field of immuno-oncology. A spin out from the …See details»
Pierre Fabre and H-Immune Partner on Anticancer Antibodies
Mar 21, 2017 H-Immune will receive undisclosed R&D funding and potential future milestone payments. H-Immune is a newly established spinout from the French Atomic Energy …See details»
HiFiBiO Therapeutics Acquires H-Immune Therapeutics
Oct 15, 2018 About H-Immune Therapeutics Established in 2016, as a spin‐out of the French Atomic Energy Commission by Co‐founders Luc Boblet, PhD, (former Co‐founder and CEO of …See details»
Redefining the immune landscape of hepatitis A virus infection
6 days ago Hepatitis A virus (HAV), first identified in 1973 1, is a small non-enveloped virus in the Picornaviridae family, with a positive-strand RNA genome of 7,500 nucleotides in length …See details»
HiFiBiO Therapeutics Acquires H-Immune Therapeutics
H-Immune has pioneered a unique in vitro immunization-based fully human antibody generation platform (IVI), which complements HiFiBiO’s world-leading single-cell platform, and has …See details»